Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I/II, Two-Part, Multicenter First-in-Human Study of Ifinatamab Deruxtecan (DS-7300a, I-DXd) in Subjects With Advanced Solid Malignant Tumors (IDeate-PanTumor01)

NCT04145622 is registered in ClinicalTrials.gov with Daiichi Sankyo as lead sponsor.

NCT NCT04145622
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04145622 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I/II, Two-Part, Multicenter First-in-Human Study of Ifinatamab Deruxtecan (DS-7300a, I-DXd) in Subjects With Advanced Solid Malignant Tumors (IDeate-PanTumor01)
Lead sponsor
Daiichi Sankyo
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
November 3, 2019
Completion date
October 31, 2029
Enrollment
247 (actual)
Sites
23

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumor, malignant solid tumor